Since CD3+ T-cells seem to respond to CCL2 in the inflamed parenchyma in the human glioma and monkey brain, we analyze their ability to express the CCL2 receptor (CCR2) in their cell surface. This evidence concerns the gene CCL2 and central nervous system cancer.